risperidone has been researched along with cariprazine in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, XW; Fu, L; Li, JQ; Sun, YY | 1 |
| Adham, N; Ferguson, P; Grayson, B; Gyertyán, I; Kiss, B; Neill, JC | 1 |
| Barabássy, Á; Bitter, I; Czobor, P; Debelle, M; Durgam, S; Fleischhacker, WW; Harsányi, J; Laszlovszky, I; Marder, S; Németh, G; Szalai, E; Szatmári, B | 1 |
| Akehurst, R; Götze, Á; Horváth, M; Kóczián, K; Molnár, A; Németh, B; Németh, G; Vokó, Z | 1 |
| Augusto, M; Greene, M; Sweeney, SM; Touya, M; Waters, H | 1 |
| Barabássy, Á; Daniel, D; Durgam, S; Earley, W; Guo, H; Nasrallah, H; Németh, G; Patel, M; Szatmári, B; Zhong, Y | 1 |
| Chhatlani, A; Farheen, SA; Setty, MJ; Tampi, RR | 1 |
| Davis, JM; Leucht, S; Smith, RC | 1 |
| Bieńkowski, P; Misiak, B; Samochowiec, J | 1 |
| Acsai, K; Barabássy, Á; Earley, W; Harsányi, J; Laszlovszky, I; Leucht, S; Németh, G; Szalai, E; Szatmári, B | 1 |
| Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S | 1 |
| Kantrowitz, JT | 1 |
| Barabássy, Á; Dombi, ZB; Laszlovszky, I; Németh, G | 1 |
| Barabássy, Á; Dombi, ZB; Leucht, S; Levine, SZ; Szabó, P | 1 |
4 review(s) available for risperidone and cariprazine
| Article | Year |
|---|---|
Use of cariprazine in psychiatric disorders: A systematic review.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder; Humans; Piperazines; Risperidone; Schizophrenia | 2018 |
Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
Topics: Amisulpride; Antidepressive Agents; Antipsychotic Agents; Clozapine; Depression; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2019 |
Cariprazine - a novel antipsychotic drug and its place in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Humans; Male; Medication Adherence; Piperazines; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Treatment Outcome | 2018 |
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Imidazoles; Indoles; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Thiophenes | 2020 |
5 trial(s) available for risperidone and cariprazine
| Article | Year |
|---|---|
Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial.
Topics: Adult; Antipsychotic Agents; Behavioral Symptoms; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2017 |
Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone.
Topics: Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Quality-Adjusted Life Years; Risperidone; Schizophrenia; Treatment Outcome | 2017 |
Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Administration Schedule; Drug Costs; Female; Humans; Injections, Intramuscular; Male; Markov Chains; Middle Aged; Paliperidone Palmitate; Piperazines; Quality-Adjusted Life Years; Risperidone; Schizophrenia; Young Adult | 2018 |
Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Young Adult | 2019 |
Single trajectory treatment response for predominant negative symptoms: Post-hoc analysis of a clinical trial with cariprazine and risperidone.
Topics: Antipsychotic Agents; Double-Blind Method; Humans; Piperazines; Psychiatric Status Rating Scales; Risperidone; Treatment Outcome | 2023 |
5 other study(ies) available for risperidone and cariprazine
| Article | Year |
|---|---|
Synthesis and pharmacological characterization of novel N-(trans-4-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)cyclohexyl)amides as potential multireceptor atypical antipsychotics.
Topics: Amides; Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Cognition; Locomotion; Male; Piperazine; Piperazines; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Structure-Activity Relationship | 2016 |
Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.
Topics: Animals; Antipsychotic Agents; Cognition; Cognition Disorders; Conditioning, Operant; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Exploratory Behavior; Female; Motor Activity; Nootropic Agents; Phencyclidine; Piperazines; Rats; Recognition, Psychology; Risperidone; Schizophrenia; Schizophrenic Psychology; Social Behavior | 2016 |
Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Patient Outcome Assessment; Piperazines; Psychiatric Status Rating Scales; Psychometrics; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Young Adult | 2019 |
Additional perspective on cariprazine and negative symptoms.
Topics: Antipsychotic Agents; Humans; Piperazines; Risperidone | 2022 |
Addressing negative symptoms of schizophrenia pharmacologically with cariprazine: evidence from clinical trials, a real-world study, and clinical cases.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Piperazines; Risperidone; Schizophrenia | 2022 |